echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Pfizer acquires part of ARV-471 equity for 2.4 billion

    Pfizer acquires part of ARV-471 equity for 2.4 billion

    • Last Update: 2021-08-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    [News event]: Pfizer announced today that it will acquire a partial interest in the estrogen receptor PROTAC drug ARV-471 developed by Arvinas, a pioneer in protein degradation, with a down payment of 650 million and a stock subscription of 350 million, plus 1.
    4 billion potential mileage
    .


    The two will be jointly responsible for the clinical development of the drug, and the profit will be divided by 5/5.


    [Drug Source Analysis]: Avinas is the pioneer of PROTAC technology, created by the famous scientist Craig Crews
    .


    Crews invented the proteomic inhibitor Carfilzomib (Kyprolis®) and founded Proteolix to develop this drug


    There are several practical problems to achieve this goal systematically
    .


    First, although dual-target drug design has a long history, its successful cases are very limited


    However, the dose-effect relationship of PROTAC is also completely different from traditional inhibitors.
    In theory, a PROTAC drug molecule can completely degrade the target protein if it is sufficiently efficient
    .


    Because this is a catalytic process, PROTAC does not need to sit in the target binding cavity to complete the inhibitory function, and then leave to degrade the next protein molecule


    As PROTAC like ARV-471 has a certain clinical effect and does not have too serious platform-related side effects, protein degradation has quickly become a major frontier of small molecule drugs
    .


    However, it is difficult to judge the success or failure of new drugs in the early stage.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.